Across TCGA pan-cancer cohorts, ELANE Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ELANE data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ELANE Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ELANE expression acts as an unfavorable survival marker.

LIHC, BLCA, and ESCA are the cancer types where ELANE Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.029	0.556	<.001	12	view →
BLCA	DFS	Median	IV	0.090	0.469	.009	12	view →
ESCA	OS	Median	All	0.211	0.700	.020	9	view →
SKCM	OS	Median	All	0.197	0.871	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ELANE tumor-vs-normal RNA expression · all ELANE data types